CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Summary

Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to meet a high quality standard. Treatments and outcomes will be reported to the registry to allow further understanding of how genetic differences can lead to better diagnosis and treatments.

Conditions

• Neoplasms
• Lung Neoplasms
• Colon Neoplasms
• Breast Neoplasms
• Pancreatic Neoplasms
• Prostate Neoplasms
• Kidney Neoplasms
• Liver Neoplasms
• Rectal Neoplasms
• Hematologic Neoplasms
• Multiple Myeloma
• Myelodysplastic Syndromes
• Ovarian Neoplasms
• Bladder Neoplasms
• Testicular Neoplasms
• Endometrial Neoplasms
• Brain Neoplasms
• Biliary Tract Neoplasms
• Head and Neck Neoplasms
• Uterine Cervical Neoplasms
• Skin Neoplasms
• Melanoma
• Gastric Neoplasms
• Anal Neoplasms
• Sarcoma

Interventions

OTHER

Provider determined

Provider will treat patient as he/she feels best

Sponsors & Collaborators

• CureOne

  lead OTHER

Principal Investigators

• Razelle Kurzrock, M.D. · Moores Cancer Center, University of California at San Diego

• John Pfeifer, M.D., Ph.D. · Washington University School of Medicine

• Dane J. Dickson, M.D. · CureOne/Knight Cancer Center, Oregon Health and Science University

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-10-02

Primary Completion

2019-03-29

Completion

2019-03-29

Countries

• United States

Study Locations